 A fourth class of dual PPAR agonists, so-called "glitazars", which bind to both the α and γ PPAR isoforms, are currently under active investigation for treatment of a larger subset of the symptoms of the metabolic syndrome.These include the experimental compounds aleglitazar, muraglitazar and tesaglitazar.In June 2013, saroglitazar was the first glitazar to be approved for clinical use.